SHUTi OASIS for Alzheimer Disease

Phase-Based Progress Estimates
Alzheimer Disease+9 More
SHUTi OASIS - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial will study whether an internet-based cognitive behavioral therapy for insomnia can help improve sleep and cognition in people with mild cognitive impairment.

Eligible Conditions
  • Alzheimer Disease
  • Mild Cognitive Impairment (MCI)
  • Insomnia
  • Dyssomnias
  • Cognitive Decline
  • Sleep State Misperception
  • Nervous System Diseases
  • Sleeplessness
  • Sleep Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Alzheimer Disease

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

Month 24
Blood coagulation tests
Falls frequency
Insomnia Severity Index
Lawson's Instrumental Activities of Daily Living Scale
Match to Sample Visual Search
Multidimensional Fatigue Symptoms Inventory - Short Form
Paired Associates Learning
Patient-Reported Outcomes Measurement Information System (PROMIS)
Short Form-12 Health Survey (Quality of Life)
Sleep Efficiency
Sleep Onset Latency
Spatial Working Memory Test
Wake after sleep onset (WASO)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Alzheimer Disease

Trial Design

2 Treatment Groups

1 of 2
Patient Education Website
1 of 2
Experimental Treatment
Non-Treatment Group

144 Total Participants · 2 Treatment Groups

Primary Treatment: SHUTi OASIS · Has Placebo Group · Phase 2

Experimental Group · 1 Intervention: SHUTi OASIS · Intervention Types: Behavioral
Patient Education Website
PlaceboComparator Group · 1 Intervention: Patient Education · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

Who is running the clinical trial?

University of VirginiaLead Sponsor
679 Previous Clinical Trials
1,425,640 Total Patients Enrolled
5 Trials studying Alzheimer Disease
431 Patients Enrolled for Alzheimer Disease
Meghan K Mattos, PhD, RN, CNLPrincipal InvestigatorUniversity of Virginia

Eligibility Criteria

Age 65+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to comply with all study procedures and are available for the duration of the study.
You are female or male, aged ≥ 65 years of age.
You must be willing to be emailed about the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: October 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.